Additional Risks Of I.V. Anticonvulsants To Be Taken Up By FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
A joint advisory committee will determine if regulatory action is necessary to reduce risks from intravenous administration of phenytoin and fosphenytoin, including the risk of a skin disease that can lead to amputation.
You may also be interested in...
Chart: Class-Wide REMS For Anti-Epileptics Remains A Work In Progress
The epilepsy market seems poised to change with the entry of a new product following a positive advisory committee for GlaxoSmithKline/Valeant's Potiga (ezogabine), and a swift approval could be aided by an already-prepared Risk Evaluation and Mitigation Strategy (see preceding story). The risk management of many approved epilepsy products is changing as well, as sponsors implement class-wide warning of increased risk of suicidality to their products' labeling and develop a REMS including a Medication Guide. FDA issued its letter to sponsors requiring the changes Dec. 16, 2008 ("The Pink Sheet," Jan. 5, 2009), but 20 months after the safety changes were mandated, only half of the products have added a REMS. The pace of implementation is noteworthy because the 2007 legislation that FDA invoked in mandating the changes was designed to give the agency the power to swiftly make safety-related labeling changes. Getting sponsors to adopt REMS has proved more complicated.
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.